Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: NSC 130181; SR 259075; SR 4233; Tirazone; WIN 59075

Latest Information Update: 29 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SRI International; Stanford Cancer Institute
  • Developer SRI International; Teclison
  • Class Antineoplastics; Radiation-sensitising agents; Reducing agents; Small molecules; Triazines
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cervical cancer
  • Phase II Colorectal cancer; Liver cancer
  • Discontinued Glioma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 13 Nov 2017 Teclison initiates enrolment in a phase II trial for liver cancer in USA (IV) (NCT03145558)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in liver cancer in Taiwan (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top